SCHEMBL31172570

SCHEMBL31172570

O=C(O)c1ccc(Cn2cccn2)c(C2CC2)c1F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTT P42858 1/20 0.41
▸ CNR1 P21554 1/20 0.39
▸ CNR2 P34972 1/20 0.39
▸ BRD4 O60885 1/20 0.38
▸ HDAC1 Q13547 1/20 0.36
▸ HDAC6 Q9UBN7 1/20 0.36
▸ KEAP1 Q14145 1/20 0.34
▸ NFE2L2 Q16236 1/20 0.34
▸ TDP1 Q9NUW8 1/20 0.34
▸ CAMKK1 Q8N5S9 1/20 0.34
▸ CAMKK2 Q96RR4 1/20 0.34
▸ GABRA1 P14867 1/20 0.34
▸ GABRG2 P18507 1/20 0.34
▸ GABRB3 P28472 1/20 0.34
▸ GABRA5 P31644 1/20 0.34
▸ GABRA3 P34903 1/20 0.34
▸ GABRA2 P47869 1/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ TSHR P16473 1/20 0.34
▸ KMT2A Q03164 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31172526 0.86 KLKB1 (0.39) HTTCNR1CNR2BRD4HDAC1
SCHEMBL31172622 0.85 CNR1 (0.36) HTTCNR1CNR2BRD4HDAC1
SCHEMBL31172624 0.85 CNR1 (0.36) HTTCNR1CNR2BRD4HDAC1
SCHEMBL31172783 0.81 HTT (0.46) HTTCNR1CNR2BRD4HDAC1
SCHEMBL31516714 0.76 KAT7 (0.50) —
SCHEMBL31172591 0.74 HTT (0.44) HTTCNR1CNR2BRD4HDAC1
SCHEMBL31172740 0.73 HTT (0.55) HTTBRD4HDAC1HDAC6TDP1
SCHEMBL17787056 0.73 HTT (0.44) HTTHDAC1HDAC6MEN1TSHR
SCHEMBL15155447 0.72 HTT (0.56) HTTBRD4HDAC1HDAC6TDP1
SCHEMBL31172495 0.70 HTT (0.45) HTTBRD4HDAC1HDAC6TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4680226-A2 ACYLSULFONAMIDE KAT6A INHIBITORS Olema Pharmaceuticals, Inc. (US) 2026-01-21 — — EP disclosed
US-20260015327-A1 ACYLSULFONAMIDE KAT6A INHIBITORS OLEMA PHARMACEUTICALS INC (US) 2026-01-15 — — US disclosed
US-12428379-B2 Acylsulfonamide KAT6A inhibitors OLEMA PHARMACEUTICALS, INC. (US) 2025-09-30 — — US disclosed
US-20250136553-A1 ACYLSULFONAMIDE KAT6A INHIBITORS OLEMA PHARMACEUTICALS, INC. 2025-05-01 — — US disclosed
WO-2024189598-A2 ACYLSULFONAMIDE KAT6A INHIBITORS OLEMA PHARMACEUTICALS, INC. (US) 2024-09-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250136553-A1 ACYLSULFONAMIDE KAT6A INHIBITORS KAT6A, KAT2A, KAT6B HTT 508/4885CNR1 4166/4885CNR2 4380/4885
US-12428379-B2 Acylsulfonamide KAT6A inhibitors KAT6A, KAT2A, KAT6B HTT 508/4885CNR1 4166/4885CNR2 4380/4885
US-20260015327-A1 ACYLSULFONAMIDE KAT6A INHIBITORS KAT6A, KAT2A, KAT6B HTT 1323/4885CNR1 1062/4885CNR2 2827/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback